CED of cetuximab-conjugated iron oxide NPs demonstrated therapeutic effects in vivo for both EGFR-expressing glioblastoma (GBM) xenografts in mice [159] and spontaneous intracranial gliomas in dogs [160]. This evidence concerns the gene EGFR and glioblastoma.